Non-alcoholic steatohepatitis (NASH) develops from non-alcoholic fatty liver disease
(NAFLD). Currently, around 25% of the population is estimated to have NAFLD, and 25% of …

The history of anti-obesity pharmacotherapies is marked by disappointments, often
entangled with societal pressure promoting weight loss and the prevailing conviction that …

Metformin is a biguanide drug that has been used to treat type 2 diabetes mellitus for more
than 60 years. The United Kingdom Prospective Diabetic Study (UKPDS) has shown …

Highlights•Non-alcoholic steatohepatitis (NASH) is a medical disease of unmet therapeutic
need.•Numerous drugs are in various stages of clinical development for …

Nonalcoholic fatty liver disease (NAFLD) is a global epidemic that is likely to become the
most common cause of chronic liver disease in the next decade, worldwide. Though …

Non‐alcoholic steatohepatitis (NASH) is associated with a disturbed metabolism in liver,
insulin resistance, and excessive accumulation of ectopic fat. Branched‐chain amino acids …

Sildenafil, approved two decades ago, is the inhibitor of phosphodiesterase 5 (PDE5). First
of all, it was designated for angina pectoris, but soon it showed a wonderful efficacy in …

For over 60 years, metformin has been widely prescribed by physicians to treat type 2
diabetes. Along with more in-depth research on metformin and its molecular mechanism in …

Impaired muscle recovery (size and strength) following a disuse period commonly occurs in
older adults. Many of these individuals are not able to adequately exercise due to pain and …

Purpose This current study investigated the effect of metformin treatment on hepatic
oxidative stress and inflammation associated with nonalcoholic fatty liver disease (NADLD) …